Skip to main content
Nature Communications logoLink to Nature Communications
. 2020 Apr 30;11:2218. doi: 10.1038/s41467-020-15721-y

Retraction Note: An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer

D M Janzen 1, E Tiourin 1, J A Salehi 1, D Y Paik 1, J Lu 2, M Pellegrini 2,3, S Memarzadeh 1,3,4,
PMCID: PMC7192922  PMID: 32355227

Retraction of: Nature Communications 10.1038/ncomms8956, published online 3 August 2015

An investigation of archival materials initiated by the corresponding author of this paper revealed several errors that undermine the central conclusions with regards to the sensitivity of ovarian cancer tumours to the co-therapy of birinapant and carboplatin in vivo. STR profiling evaluation of archival material pertaining to several key experiments revealed that Ovcar-3 cells were used in xenografts rather than as stated, S1-GODL cells in Figs. 6b, c, 7 and Supplementary Fig. 8, patient sample II cells in Fig. 8, and MCF7 cells in Supplementary Fig. 9. Given these issues, we wish to retract the Article in its entirety. We deeply regret this circumstance and apologize to the community.


Articles from Nature Communications are provided here courtesy of Nature Publishing Group

RESOURCES